Indian healthtech firm Indegene files for IPO, Carlyle to sell stake
15 Dec 2022
IPOAcquisition
BENGALURU, Dec 15 (Reuters) - Indian health technology company Indegene Ltd has filed for an initial public offering, with private equity firm Carlyle (CG.O) looking to offload a part of its stake, draft papers filed with the market regulator showed on Thursday.
Local media reported that the Bengaluru-based company was aiming to raise over 32 billion rupees ($386.73 million) through the offering. Reuters could not immediately confirm the figure.
The IPO consists a fresh issue of shares worth 9.5 billion rupees and a sale of up to 36.3 million shares by existing shareholders, including a Carlyle entity, the filing showed.
CA Dawn Investments, a Carlyle entity which held a 20.8% stake in Indegene, will be selling up to 17.2 million shares in the offering, while Brighton Park Capital funds will offload up to 8.4 million shares, according to the filing.
Infosys (INFY.NS) co-founder NS Raghavan's Nadathur Family Office will also sell about 8 million shares in the IPO.
Indegene will use proceeds from the new share sale to pay its unit's debt, fund capital expenditure, and pay a deferred consideration for a past acquisition.
The company, which gets 66% of its revenue from North America and 27% from Europe, reported a 10% rise in net profit for the year ended March 2022. Revenue jumped 72%.
Kotak Mahindra Capital, Citigroup, J.P. Morgan and Nomura are book running lead managers to the IPO.
($1 = 82.7450 Indian rupees)
Our Standards: The Thomson Reuters Trust Principles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.